Metronomic chemotherapy for cancer treatment: a decade of clinical studies

摘要: Over the past few years, more and new selective molecules directed against specific cellular targets have become available for cancer therapy, leading to impressive improvements. In this evolving scenario, a way of delivering older cytotoxic drugs has also been developing. Many studies demonstrated that several antiangiogenic properties if administered frequently at lower doses compared with standard schedules containing maximal tolerated (MTD). Such strategy, named metronomic chemotherapy, focuses on different target: slowly proliferating tumour endothelial cells. About 10 years ago, chemotherapy was firstly enunciated hereafter many clinical experiences were published related almost any disease. This review analyses dealing its combination targeted agents in solid tumours. A computerized literature search MEDLINE performed using following terms: OR “continuous low dose” AND Satisfactory results achieved diverse types, such as breast prostate or paediatric sarcomas. Moreover, reported determined minimal toxicity MTD chemotherapy. Overall, series are very heterogeneous often reporting retrospective data, while only randomized trials. These limitations still prevent draw definitive conclusions types. Large well-designed eagerly awaited confirming promises their combinations molecules.